Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Fast homogeneous assay for plasma procarboxypeptidase U.

Schatteman KA, Goossens FJ, Leurs J, Kasahara Y, Scharpé SS, Hendriks DF.

Clin Chem Lab Med. 2001 Sep;39(9):806-10.

PMID:
11601677
2.

Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.

Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF.

Clin Chem. 1999 Jun;45(6 Pt 1):807-13.

3.

Proteolytic activation of purified human procarboxypeptidase U.

Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.

Clin Chim Acta. 2000 Feb 25;292(1-2):25-40.

PMID:
10686274
4.

Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.

Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.

Thromb Haemost. 1999 Dec;82(6):1718-21.

PMID:
10613660
5.

Carboxypeptidase N: colorimetric assay using a new substrate.

Hendriks D, Scharpe S, van Sande M, Lommaert MP, Kasahara Y.

Anal Biochem. 1987 Jul;164(1):90-5.

PMID:
3118736
6.
7.

Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.

Leenaerts D, Bosmans JM, van der Veken P, Sim Y, Lambeir AM, Hendriks D.

J Thromb Haemost. 2015 Dec;13(12):2227-32. doi: 10.1111/jth.13135. Epub 2015 Nov 12.

PMID:
26340515
8.

Colorimetric determination of carboxypeptidase A activity in serum.

Saruta H, Ashihara Y, Sugiyama M, Roth M, Miyagawa E, Kido Y, Kasahara Y.

Clin Chem. 1986 May;32(5):748-51.

10.

Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma.

Strömqvist M, Schatteman K, Leurs J, Verkerk R, Andersson JO, Johansson T, Scharpé S, Hendriks D.

Thromb Haemost. 2001 Jan;85(1):12-7.

PMID:
11204563
11.

Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.

Leenaerts D, Aernouts J, Van Der Veken P, Sim Y, Lambeir AM, Hendriks D.

Thromb Haemost. 2017 Jul 6;117(8):1498-1508. doi: 10.1160/TH17-02-0097. [Epub ahead of print]

PMID:
28692110
12.

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.

Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME.

Anal Biochem. 2008 Jan 1;372(1):32-40. Epub 2007 Sep 29.

PMID:
17967438
14.
15.

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Willemse JL, Heylen E, Nesheim ME, Hendriks DF.

J Thromb Haemost. 2009 Dec;7(12):1962-71. doi: 10.1111/j.1538-7836.2009.03596.x. Epub 2009 Aug 28. Review.

16.
17.

Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.

Plug T, Marquart JA, Marx PF, Meijers JC.

J Thromb Haemost. 2015 Nov;13(11):2093-101. doi: 10.1111/jth.13133. Epub 2015 Sep 30.

PMID:
26341360
18.

Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.

Knecht W, Willemse J, Stenhamre H, Andersson M, Berntsson P, Furebring C, Harrysson A, Hager AC, Wissing BM, Hendriks D, Cronet P.

FEBS J. 2006 Feb;273(4):778-92.

19.

Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.

Willemse JL, Hendriks DF.

Clin Chem. 2006 Jan;52(1):30-6. Epub 2005 Nov 18. Review.

20.

Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.

Zhou X, Declerck PJ.

J Thromb Haemost. 2015 Jun;13(6):1084-9. doi: 10.1111/jth.12894. Epub 2015 Apr 6.

Supplemental Content

Support Center